GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirona Biochem Corp (TSXV:SBM) » Definitions » Debt-to-EBITDA

Sirona Biochem (TSXV:SBM) Debt-to-EBITDA : -0.89 (As of Jan. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sirona Biochem Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sirona Biochem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.79 Mil. Sirona Biochem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$1.56 Mil. Sirona Biochem's annualized EBITDA for the quarter that ended in Jan. 2024 was C$-2.65 Mil. Sirona Biochem's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -0.89.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sirona Biochem's Debt-to-EBITDA or its related term are showing as below:

TSXV:SBM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.71   Med: -0.36   Max: -0.13
Current: -0.99

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sirona Biochem was -0.13. The lowest was -2.71. And the median was -0.36.

TSXV:SBM's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs TSXV:SBM: -0.99

Sirona Biochem Debt-to-EBITDA Historical Data

The historical data trend for Sirona Biochem's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirona Biochem Debt-to-EBITDA Chart

Sirona Biochem Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.35 -0.30 -0.37 -0.13 -0.94

Sirona Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.52 -0.92 -1.08 -0.89

Competitive Comparison of Sirona Biochem's Debt-to-EBITDA

For the Biotechnology subindustry, Sirona Biochem's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sirona Biochem's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Debt-to-EBITDA falls into.



Sirona Biochem Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sirona Biochem's Debt-to-EBITDA for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.644 + 1.539) / -2.333
=-0.94

Sirona Biochem's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.791 + 1.556) / -2.648
=-0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


Sirona Biochem  (TSXV:SBM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sirona Biochem Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sirona Biochem's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sirona Biochem (TSXV:SBM) Business Description

Traded in Other Exchanges
Address
C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L3
Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. It has a business presence in Canada and France.

Sirona Biochem (TSXV:SBM) Headlines